文献速递临床试验与 GCP流行病学与生物统计

成人ICU中鼻腔碘伏消毒剂与鼻腔莫匹罗星抗生素在氯己定沐浴条件下预防感染的随机临床试验

Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该实用性整群随机非劣效试验在美国社区医院成人ICU中比较鼻腔碘伏与莫匹罗星联合氯己定沐浴的通用去定植效果。碘伏组金黄色葡萄球菌临床培养的风险比高于基线(HR 1.17),莫匹罗星组与基线相当(HR 0.99),两组风险比差异为18.4%(95%CI 10.7%-26.6%),碘伏未达到非劣效标准。

要点

  • 碘伏组金黄色葡萄球菌临床培养风险比较基线升高(HR 1.17,原始率5.0 vs 4.3/1000 ICU归因日)。
  • 莫匹罗星组金黄色葡萄球菌临床培养风险比与基线持平(HR 0.99,原始率4.1 vs 4.0/1000 ICU归因日)。
  • 碘伏未达到非劣效标准,结果与鼻腔碘伏劣于鼻腔莫匹罗星一致。

核心结论

  • 在成人ICU患者每日氯己定沐浴背景下,鼻腔碘伏消毒剂未达到金黄色葡萄球菌临床培养结局的非劣效标准。
  • 结果与鼻腔碘伏劣于鼻腔莫匹罗星一致。

研究设计与样本

  • 两组非劣效实用性整群随机试验,在美国社区医院开展,基线时所有医院ICU均使用莫匹罗星-氯己定进行通用去定植。
  • 纳入137家随机化医院的成人ICU患者,基线期为2015年5月1日至2017年4月30日,干预期为2017年11月1日至2019年4月30日。
  • 干预为改用碘伏-氯己定(干预组)或继续莫匹罗星-氯己定(基线组),共纳入233个ICU的801668例入院。

主要发现

  • 金黄色葡萄球菌临床分离株:碘伏-氯己定干预期vs基线期HR 1.17(原始率5.0 vs 4.3/1000 ICU归因日),莫匹罗星-氯己定HR 0.99(原始率4.1 vs 4.0/1000 ICU归因日),莫匹罗星-氯己定风险比差异显著低18.4%(95%CI 10.7%-26.6%,P<.001)。
  • MRSA临床培养:碘伏-氯己定HR 1.13(原始率2.3 vs 2.1/1000 ICU归因日),莫匹罗星-氯己定HR 0.99(原始率2.0 vs 2.0/1000 ICU归因日),莫匹罗星-氯己定风险比差异显著低14.1%(95%CI 3.7%-25.5%,P=.007)。
  • 全病原体血流感染:碘伏-氯己定HR 1.00(2.7 vs 2.7/1000),莫匹罗星-氯己定HR 1.01(2.6 vs 2.6/1000),风险比差异无统计学意义(-0.9%,95%CI -9.0%至8.0%,P=.84)。
  • 与2009-2011年试验相比,莫匹罗星-氯己定组相对于未去定植的30天风险相对降低:金黄色葡萄球菌临床培养当前试验48.1%(95%CI 35.6%-60.1%),2009-2011年试验58.8%(95%CI 47.5%-70.7%);血流感染率当前试验70.4%(95%CI 62.9%-77.8%),2009-2011年试验60.1%(95%CI 49.1%-70.7%)。

关键数值与推荐

  • 主要结局为ICU归因金黄色葡萄球菌临床培养,预设非劣效界值为10%。
  • 参与者平均(SD)年龄63.4(17.2)岁,女性占46.3%,平均(SD)ICU住院时长4.8(4.7)天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Universal nasal mupirocin plus chlorhexidine gluconate (CHG) bathing in intensive care units (ICUs) prevents methicillin-resistant Staphylococcus aureus (MRSA) infections and all-cause bloodstream infections. Antibiotic resistance to mupirocin has raised questions about whether an antiseptic could be advantageous for ICU decolonization. OBJECTIVE: To compare the effectiveness of iodophor vs mupirocin for universal ICU nasal decolonization in combination with CHG bathing. DESIGN, SETTING, AND PARTICIPANTS: Two-group noninferiority, pragmatic, cluster-randomized trial conducted in US community hospitals, all of which used mupirocin-CHG for universal decolonization in ICUs at baseline. Adult ICU patients in 137 randomized hospitals during baseline (May 1, 2015-April 30, 2017) and intervention (November 1, 2017-April 30, 2019) were included. INTERVENTION: Universal decolonization involving switching to iodophor-CHG (intervention) or continuing mupirocin-CHG (baseline). MAIN OUTCOMES AND MEASURES: ICU-attributable S aureus clinical cultures (primary outcome), MRSA clinical cultures, and all-cause bloodstream infections were evaluated using proportional hazard models to assess differences from baseline to intervention periods between the strategies. Results were also compared with a 2009-2011 trial of mupirocin-CHG vs no decolonization in the same hospital network. The prespecified noninferiority margin for the primary outcome was 10%. RESULTS: Among the 801 668 admissions in 233 ICUs, the participants' mean (SD) age was 63.4 (17.2) years, 46.3% were female, and the mean (SD) ICU length of stay was 4.8 (4.7) days. Hazard ratios (HRs) for S aureus clinical isolates in the intervention vs baseline periods were 1.17 for iodophor-CHG (raw rate: 5.0 vs 4.3/1000 ICU-attributable days) and 0.99 for mupirocin-CHG (raw rate: 4.1 vs 4.0/1000 ICU-attributable days) (HR difference in differences significantly lower by 18.4% [95% CI, 10.7%-26.6%] for mupirocin-CHG, P < .001). For MRSA clinical cultures, HRs were 1.13 for iodophor-CHG (raw rate: 2.3 vs 2.1/1000 ICU-attributable days) and 0.99 for mupirocin-CHG (raw rate: 2.0 vs 2.0/1000 ICU-attributable days) (HR difference in differences significantly lower by 14.1% [95% CI, 3.7%-25.5%] for mupirocin-CHG, P = .007). For all-pathogen bloodstream infections, HRs were 1.00 (2.7 vs 2.7/1000) for iodophor-CHG and 1.01 (2.6 vs 2.6/1000) for mupirocin-CHG (nonsignificant HR difference in differences, -0.9% [95% CI, -9.0% to 8.0%]; P = .84). Compared with the 2009-2011 trial, the 30-day relative reduction in hazards in the mupirocin-CHG group relative to no decolonization (2009-2011 trial) were as follows: S aureus clinical cultures (current trial: 48.1% [95% CI, 35.6%-60.1%]; 2009-2011 trial: 58.8% [95% CI, 47.5%-70.7%]) and bloodstream infection rates (current trial: 70.4% [95% CI, 62.9%-77.8%]; 2009-2011 trial: 60.1% [95% CI, 49.1%-70.7%]). CONCLUSIONS AND RELEVANCE: Nasal iodophor antiseptic did not meet criteria to be considered noninferior to nasal mupirocin antibiotic for the outcome of S aureus clinical cultures in adult ICU patients in the context of daily CHG bathing. In addition, the results were consistent with nasal iodophor being inferior to nasal mupirocin. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03140423.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Huang SS, Septimus EJ, Kleinman K, et al. Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial. JAMA. 2023. PMID: 37815567. doi:10.1001/jama.2023.17219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。